Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group BL.7 (EORTC 30987) - Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients with Metastatic or Locally Advanced Urothelial Cancer without Prior Systemic Therapy

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R.
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Feb 27. [Epub ahead of print]

http://jco.ascopubs.org/content/early/2012/02/27/JCO.2011.38.6979.abstract

________________________________________________

Canadian Cancer Trials Group BR.18 - A Phase II/III Double Blind Randomized Trial of BMS-275291 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

This publication included tissue samples from 2 cohorts: non-small cell lung cancer diagnosed in 1999 in Manitoba and advanced non-small cell lung cancer patients from the Canadian Cancer Trials Group BR.18 trial.

Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, Bradbury P, Leighl N, Shepherd F, Nowatzki J, Demers A, Murphy L. Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer (ONLINE). Hormones and Cancer 1-8, 2012.

http://dx.doi.org/10.1007/s12672-012-0105-y
________________________________________________

Canadian Cancer Trials Group IND.162 - A Phase I Study of Temozolomide and RAD001C in Patients with Malignant Glioma

Mason W, MacNeil M, Kavan P, Easaw J, MacDonald D, Thiessen B, Urva S, Lwin Z, McIntosh L, Eisenhauer E. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an Canadian Cancer Trials Group study (ONLINE). Invest New Drugs 1-8, 2011.

http://www.springerlink.com/content/c7k7r7028khm4801/

________________________________________________

Canadian Cancer Trials Group OV.17 (GINECO CALYPSO) - A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (Caelyx) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (> 6 months): GCIG Calypso Study

Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer 106: 633-7, 2012.

http://www.nature.com/bjc/journal/v106/n4/abs/bjc2011593a.html?WT.ec_id=BJC-201202